Katharina A.M. Lindner

MHC class II-restricted antigen presentation is required to prevent dysfunction of cytotoxic T cells by blood-borne myeloids in brain tumors

Michael Kilian, Ron Sheinin, Chin Leng Tan et al. · Cancer Cell · 2023 · 114 citations

Life Sciences, Immunology, Oncology +16

A H3K27M-targeted vaccine in adults with diffuse midline glioma

Isabel Poschke, Katharina A.M. Lindner, Lukas Bunse et al. · Nature Medicine · 2023 · 78 citations · Full text

Medicine, Immunology, Oncology +17

Prediction of tumor-reactive T cell receptors from scRNA-seq data for personalized T cell therapy

Chin Leng Tan, Katharina A.M. Lindner, Tamara Boschert et al. · Nature Biotechnology · 2024 · 71 citations · Full text

Life Sciences, Immunology, Oncology +17

AMPLIFY-NEOVAC: a randomized, 3-arm multicenter phase I trial to assess safety, tolerability and immunogenicity of IDH1-vac combined with an immune checkpoint inhibitor targeting programmed death-ligand 1 in isocitrate dehydrogenase 1 mutant gliomas

Lukas Bunse, Anne-Kathleen Rupp, Isabel Poschke et al. · Neurological Research and Practice · 2022 · 40 citations · Full text

Life Sciences, Immunology, Oncology +17

H3K27M neoepitope vaccination in diffuse midline glioma induces B and T cell responses across diverse HLA loci of a recovered patient

Tamara Boschert, Kristina Kromer, Taga Lerner et al. · Science Advances · 2024 · 16 citations · Full text

Life Sciences, Immunology, Oncology +17